x

Posted 02 February, 2024

SAB Biotherapeutics, Inc. appointed Samuel J. Reich as new CEO

Nasdaq:SABS appointed new Chief Executive Officer Samuel J. Reich in a 8-K filed on 02 February, 2024.


  Following the appointment of Samuel J. Reich as Chief Executive Officer, Eddie J. Sullivan will continue to serve as the President of the Company and as a member of the Board.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of SAB Biotherapeutics, Inc.
None • None
SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company. It is engaged in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. The firm produces human polyclonal immunotherapies and its versatile DiversitAb platform is applicable for unmet needs in human diseases. SAB Biotherapeutics was founded by Eddie J. Sullivan and Christine E. Hamilton in July 2014 and is headquartered in Sioux Falls, SD.
Market Cap
$49.5M
View Company Details
SAB Biotherapeutics, Inc. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 30, 2024, Samuel J. Reich, age 49, the Executive Chairman of the Board of Directors (the "Board") of SAB Biotherapeutics, Inc. (the "Company"), was appointed Chief Executive Officer of the Company, effective immediately. 

Following the appointment of Samuel J. Reich as Chief Executive Officer, Eddie J. Sullivan will continue to serve as the President of the Company and as a member of the Board. He will report to the Board and maintain leadership of operational, research and development functions of the Company. 

Mr. Reich has served as Executive Chairman of the Board since the Company's business combination with Big Cypress Acquisition Corp in October 2021 and prior to that was Chief Executive Officer, Chief Financial Officer and a member on the board of directors of Big Cypress Acquisition Corp since its inception in November 2020. Mr. Reich co-founded Biscayne Neurotherapeutics, Inc. in 2011 and served as its Executive Chairman until its sale to Supernus Pharmaceuticals (Nasdaq: SUPN) in October 2018. Biscayne Neurotherapeutics was focused on novel treatments for seizure disorders. Previously, Mr. Reich was the Executive Vice President of OPKO Ophthalmologics, a division of OPKO Health, Inc. (Nasdaq:OPK) from March 2007 to November 2008, where Mr. Reich served on the executive committee and lead the Ophthalmologics business division. Prior to his position at OPKO, Mr. Reich was the Founder and Executive Vice President of Acuity Pharmaceuticals, Inc., where he worked from July 2002 through March 2007, at which time Acuity Pharmaceuticals merged with OPKO Health. Mr. Reich was a doctoral candidate in the Department of Ophthalmology at the University of Pennsylvania Medical School. He left graduate school prior to the completion of his Ph.D. to establish Acuity. Prior to that, he was a graduate student at the University of Pennsylvania in the Biomedical Studies graduate program. He has authored six peer-reviewed scientific publications and is currently an inventor on fourteen issued U.S. patents and over 50 issued foreign patents. Mr. Reich holds a B.A. with High Honors in Biochemistry from Clark University, cum laude, Phi Beta Kappa.

There are no family relationships between Mr. Reich and the directors, nor between Mr. Reich and any executive officer, of the Company.